Core Viewpoint - The company will showcase its pipeline asset CS2015, a dual-specific antibody targeting OX40L and TSLP, at the 2025 ACAAI annual scientific meeting, marking its international debut [1] Group 1: Company Developments - CS2015 is designed with an asymmetric molecular structure that targets two key regulatory factors effective in blocking type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic characteristics for prolonged dosing intervals [1] - The stability of CS2015 supports the development of high-concentration subcutaneous formulations, while its excellent developability lays the foundation for high-yield and large-scale production [1] Group 2: Industry Context - The ACAAI is recognized as one of the most influential academic conferences in the fields of allergy, asthma, and immunology, attracting numerous experts and scholars globally to discuss the latest research findings [1]

Core Viewpoint - Company will showcase its pipeline asset CS2015 at the 2025 ACAAI annual scientific meeting, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulatory factors that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, aiming to extend its in vivo circulation half-life and optimize pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website [1]

Core Viewpoint - Company will showcase its pipeline asset CS2015 at the upcoming ACAAI annual scientific meeting in 2025, marking its first appearance at an international academic conference [1] Group 1: Company Developments - CS2015 is a bispecific antibody targeting OX40L and TSLP, which are key regulators that effectively block type 2 inflammation [1] - The molecule features a mutated Fc to reduce binding with FcγR, thereby extending its half-life in circulation and optimizing pharmacokinetic (PK) characteristics for prolonged dosing intervals [1] - CS2015 demonstrates excellent molecular stability, supporting the development of high-concentration subcutaneous formulations and ensuring scalability for production [1] Group 2: Industry Context - ACAAI is one of the most influential academic conferences in the field of allergy, asthma, and immunology, attracting experts from around the world to discuss the latest research findings [1] - The complete abstract and electronic poster for CS2015 have been officially published on the ACAAI website, enhancing visibility within the scientific community [1]

Major Events - Different Group (06090) is set to launch its IPO from September 15 to September 18, with an expected listing date of September 23 [1] - Hesai Technology-W (02525) has received 168.65 times subscription for its public offering in Hong Kong, with a share price of HKD 212.80 [1] - Basilea Pharmaceutica-B (02616) will showcase CS2015 (OX40L/TSLP bispecific antibody) at ACAA 2025 [1] - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for ALMB-0166 to treat Parkinson's disease [1] - Kingdee International (00268) plans to acquire a 62.764% stake in Yunzhijia for HKD 68.25 million [1] - Lion Group Holdings (02562) intends to acquire a company leading in AI, blockchain, decentralized finance, and stablecoin innovation [1] - COSCO Shipping Holdings (01919) plans to invest CNY 370 million to establish a joint venture [1] - Shoujia Technology (00103) aims to set up a joint venture for a super new materials company [1] - CITIC Limited (00267) has its "data-driven high-end mining equipment intelligent factory" recognized as a 2025 excellent-level intelligent factory by the Ministry of Industry and Information Technology [1] - Eden Software (01147) has its self-developed "Easy AI multimodal content generation" algorithm approved for algorithm filing in Shenzhen [1] Operating Performance - Hong Kong Dragon Land (06968) reported a contract sales amount of approximately CNY 3.602 billion for the first eight months, a year-on-year decrease of 0.16% [1] - China Southern Airlines (01055) saw an 8-month passenger turnover increase of 5.97% year-on-year [1] - China Eastern Airlines (00670) reported an 8-month passenger turnover increase of 8.72% year-on-year [1] - Air China (00753) recorded a 2.3% year-on-year increase in passenger capacity input and a 3.2% increase in passenger turnover for August [1] - Hong Kong Technology Exploration (01137) reported an August total merchandise transaction value of HKD 678 million in its e-commerce business, a year-on-year decline of 4.5% [1]

Core Viewpoint - Company shares of 基石药业-B (02616) rose over 4%, currently at 10.43 HKD with a trading volume of 109 million HKD, following the announcement of its CS2015 dual-specificity antibody being selected for presentation at the 2025 ACAAI annual scientific meeting in Orlando [1] Group 1: Company Pipeline and Developments - CS2015, a dual-specificity antibody targeting OX40L and TSLP, is recognized for its potential as a first-in-class/best-in-class treatment for type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease [1] - The upcoming ACAAI conference will take place from November 6 to 10 in Orlando, where CS2015 will be showcased through an electronic poster presentation and live oral report [1] Group 2: Market Potential and Clinical Advancements - 国投证券 highlighted that the early pipeline of the company includes several promising ADC products such as CS5007, CS5008, CS5005, CS5006, and CS5009, along with autoimmune pipeline products like CS2013 and CS2015, indicating a strong potential for differentiated offerings [2] - The clinical advancement of these products is expected to be closely monitored due to their high potential in the market [2]

Core Viewpoint - Company announced that its pipeline asset CS2015, a dual-specific antibody targeting OX40L and TSLP, has been selected for presentation at the 2025 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, scheduled for November 6-10 in Orlando, USA [1] Group 1: Product Development - CS2015 is a potential first-in-class/best-in-class dual-specific antibody that targets both OX40L and TSLP [1] - The antibody aims to provide new treatment strategies for type 2 inflammatory diseases such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) by dual inhibition of key regulatory factors involved in Th2-mediated inflammatory responses [1]

Core Viewpoint - Company’s CS2015, a dual-specific antibody targeting OX40L and TSLP, has been selected for presentation at the 2025 ACAAI Annual Scientific Meeting, highlighting its potential in treating type 2 inflammatory diseases [1] Group 1: Product Development - CS2015 is a potential first-in-class/best-in-class dual-specific antibody that targets both OX40L and TSLP [1] - The antibody aims to provide new treatment strategies for atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) by dual inhibition of key regulatory factors in Th2-mediated inflammatory responses [1] Group 2: Conference Participation - The ACAAI Annual Scientific Meeting will take place from November 6 to 10 in Orlando, USA, where CS2015 will be showcased through an electronic poster presentation and live oral presentation [1]

Core Viewpoint - Company Basilea Pharmaceutica has announced that its pipeline candidate CS2015 has been selected for presentation at the 2025 ACAAI Annual Scientific Meeting, highlighting its potential in treating type 2 inflammatory diseases [1] Group 1: Product Development - CS2015 is a dual-specific antibody targeting both OX40L and TSLP, representing a potential first-in-class or best-in-class therapy [1] - The drug aims to provide new treatment strategies for atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) by dual inhibition of key regulatory factors in Th2-mediated inflammatory responses [1] Group 2: Event Participation - The ACAAI Annual Scientific Meeting will take place from November 6 to 10 in Orlando, USA, where CS2015 will be showcased through an electronic poster presentation and live oral presentation [1]